Please login to the form below
Chiesi
This page shows the latest Chiesi news and features for those working in and with pharma, biotech and healthcare.
Chiesi's ultra-rare genetic disorder therapy wins European backing
Chiesi's ultra-rare genetic disorder therapy wins European backing. Lamzede is set to become the first approved therapy for Alpha-Mannosidosis. ... It’s the second most advanced product from Chiesi’s rare disease unit after its LSCD therapy Holoclar
Latest news
-
AZ’s COPD triple data sets up market clash with GSK
In Europe it was pipped to the post by Chiesi, which got a green light for its Trimbow (formoterol fumarate, glycopyrronium and beclomethasone) product, but this medicine must be administered
-
With US approval, GSK now needs rapid uptake for COPD triple
In August, Chiesi won EU approval for its closed triple therapy Trimbow (beclometasone, formoterol and glycopyrronium), but that is administered twice-daily.
-
Prix Galien opens for entries with new award
Chiesi’s Holoclar, the first stem cell therapy to receive European marketing approval, won the Orphan Product Award.
-
NICE backs Europe's first stem cell therapy
said its appraisal committee had agreed that Chiesi had presented evidence to show that Holoclar "offered several advantages over existing treatments". ... Chiesi has agreed to supply Holoclar to the NHS at an undisclosed discount to its list price of
-
Chiesi Group's Trimbow wins European licence
Chiesi Group's Trimbow wins European licence. European Commission approves the COPD treatment. ... The European Commission has approved Chiesi Group’s Trimbow to treat adults with moderate to severe chronic obstructive pulmonary disease (COPD) who are
More from news
Approximately 12 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
The good, the bad and the ugly
GSK, AZ and Chiesi are each playing in this new market.
-
Deal Watch May 2016
911. The Medicines Company/ Chiesi. Product acquisition. Acquisition of cardiovascular assets Cleviprex, Kengreal and rights to Argatroban.
-
Anticipating the future in healthcare
The technology was licensed from the Dutch bio company uniQure BV by Chiesi, a mid-sized, family-owned pharma company based in Parma, Italy. ... Paolo Chiesi, chairman of the board of directors, and Andrea Chiesi, CEO of Chiesi Farmaceutici, are part of
-
Deal Watch table for September 2013
Cornerstone Therapeutics/ Chiesi Farmaceutici. Acquisition (42 per cent). US speciality pharmaceutical company focused hospital and niche respiratory products. ... 2. Global rights excluding India, Pakistan and China. 3. Acquisition of the shares not
-
Pharma deals during October 2012
In keeping with Chiesi's marketing capabilities, the licence is for certain countries, including Europe, Turkey and CIS countries. ... 58. † Veloxis Pharmaceuticals / Chiesi Farmaceutici. Licence. LCP-Tacro (tacrolimus) immunosuppressant for kidney
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
Akinion’s Dr Richard Jones joins Holostem Terapie Avanzate
Dr Paolo Chiesi, chairman of the board at Holostem, said: “ On behalf of the Holostem board, I am delighted to welcome Richard to the company. “
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
CAN advertising
AbbVie. ALK. Chiesi. Eisai. KIMS. LEO Pharma. Otsuka. Sanofi Pasteur MSD.
-
M&F Health
Alere. British Association for Sexual Health and HIV (BASHH). Chiesi. Danone.
-
Random42 Scientific Communication
Boston Biomedical. Boston Scientific . Bristol-Myers Squibb. BTG. Celgene. Ceva. Chiesi. Cidara Therapeutics.
-
Swordfish Advertising
Archimedes Pharma. Corporate. Chiesi. Fostair. Corporate. Clenil. Atimos. Danone. Infant feeding.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Great salary and bebefits
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Senior Account Manager / Account Director
-
Great salary and bebefits
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
-
Senior Medical Writer
-
Great salary and benefits
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
-
Senior Programme Executive
-
Salary TBC
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
-
Scientific Director
-
Great salary and bebefits
- Account Manager – Med Comms – London
-
Salary TBC
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
Subscribe to our email news alerts
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- The Holy Grail of HCP Access
- This is the data you need to gain access....
- No incentive for a cure
- The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
- Why heading online for scientific meetings can yield greater HCP engagement
- Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
Quick links
Infographics
